Antifungal pulse therapy for onychomycosis: A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole

Archives of Dermatology

Volumn 132, Issue 1, 1996, Pages 34-41

  De Doncker, Piet ^a,b,c,d   Decroix, Jacques ^c   Piérard, Gérald E ^e   Roelant, Dirk ^d   Woestenborghs, Robert ^d   Jacqmin, Philippe ^c   Odds, Frank ^c   Heremans, Annie ^c   Dockx, Pierre ^a   Roseeuw, Diane ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c Janssen Research Foundation ^*  (Belgium)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; INSULIN; ITRACONAZOLE; POTASSIUM HYDROXIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; FUNGUS CULTURE; GOOD CLINICAL PRACTICE; HUMAN; HUMAN TISSUE; MALE; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION; TRICHOPHYTON RUBRUM;

AGED; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; ITRACONAZOLE; MALE; NAILS; ONYCHOMYCOSIS; TRICHOPHYTON;

EID: 9044222883     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.132.1.34     Document Type: Article

References (69)

1. Prevalence, morbidity and cost of dermatological diseases. J Invest Dermatol 1979,75:395-401 Editorial.
2. Pardo-Castello V, Pardo OA. Disease of the Nails. 3rd ed. Springfield, III. Charles C Thomas Publisher; 1960:36-45.
3. Williams HC. The epidemiology of onychomycosis in Britain Br J Dermatol. 1993;129.101-109.
4. Grigoriu D, Grigoriu A Les onychomycoses. Rev Med Suisse Romande 1975, 95:839-849.
5. Haneke E. Fungal infections of the nail. Semin Dermatol. 1991;10:41-53.
6. Ramesh V, Reddy BSN, Singh R Onychomycosis. Int J Dermatol. 1983.22 148-152
7. André J, Achten G. Onychomycosis Int J Dermatol. 1987;26:481-490
8. Lubeck DP, Patrick DL, McNulty P, Fifre SK, Birnbaum J. Quality of life of persons with onychomycosis. Qual Life Res 1993;2:341-348.
9. Baran R, Badillet G. Un dermatophyte unguéal est-il nécessairement pathogène? Ann Dermatol Venereol. 1983;110:629-631.
10. De Doncker P. Pharmacokinetics of onychomycosis In: Jacobs J. Nall L, eds. Selected Topics in Medical Mycology. New York, NY: Marcel Dekker Inc. In press.
11. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis BMJ. 1967;3:464-468.
12. Hay RJ, Baran R, Haneke E. Fungal (onychomycosis) and other infections involving the nail apparatus. In: Baran R, Dawber R, eds Diseases of the Nail and Their Management. 2nd ed. Boston, Mass: Blackwell Scientific Publications Inc, 1994:97-134.
13. Piérard GE, Arrese JE, Piérard-Franchimont C Treatment of onychomycosis: traditional approaches. J Am Acad Dermatol. 1993,29 S41-S45.
14. Zaias N. Onychomycosis Dermatol Clin. 1985,3:445-460
15. Zaias N, Drackman D. A method for the determination of drug effectiveness in onychomycosis. J Am Acad Dermatol 1983;9:912-919.
16. Holub PG, Hubbard ER. Ketoconazole in the treatment of onychomycosis. J Am Podiatr Med Assoc. 1987;77.338-339
17. Hay R, Clayton YM, Griffiths WAD, Dowd PM A comparative study of ketoconazole and griseofulvin in dermatophytosis. Br J Dermatol. 1985,112 691-696
18. Petranyi G, Ryder NS, Stub A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase Science. 1984,224: 1239-1241.
19. Haley L, Daniel RC III Fungal infections. In: Scher R, Daniel RC. Nails: Therapy. Diagnosis, Surgery. Philadelphia, Pa: WB Saunders Co; 1990 106-119
20. Jenssen JC. Clinical pharmacokinetics of terbinafine (Lamasil). Clin Exp Dermatol 1992,126(suppl 39) 28-32
21. Goodfield MJD. Clinical results with terbinafine in onychomycosis. J Dermatol Treat. 1990;1(suppl 2) 55-57.
22. Goodfield MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol. 1992;126(suppl 39):33-35.
23. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelman R. Treatment of onychomycosis with terbinafine. Br J Dermatol. 1992;126(suppl 39):40-46.
24. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of skin and nails J Dermatol Treat 1990;1(suppl 2):33-38.
25. Grant SM, Clissold SP. Fluconazole. a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs. 1990,39:877-916.
26. Hay RJ Pharmacodynamic and pharmacokinetic evaluation of fluconazole in skin and nails. Int J Dermatol. 1992;31(suppl 2):6-7
27. Fraki J, Heikkila H, Kero M, et al. Fluconazole in the treatment of onychomycosis, an open non-comparative multicenter study with oral 150 mg fluconazole once-weekly. In: Proceedings of Dermatology 2000; May 18-21, 1993; Vienna Austria. Abstract 103.
28. Monteiro-Gei F, Melendez M, Sties L Fluconazole in the treatment of onychomycosis. In: Program and abstracts of the XI Congress of the International Society for Human and Animal Mycology. Montreal, Quebec: ISHAM, 1991: 142.
29. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically and parenterally administered itraconazole in the treatment of superficial and deep mycoses, animal models. Rev Infect Dis. 1987;9(suppl 1).15-32.
30. Delescluse J, Cauwenbergh G, Degreef H Itraconazole, a new orally active antifungal in the treatment of pityriasis versicolor Br J Dermatol 1986,114:701-703.
31. De Doncker P, Cauwenbergh G. L'itraconazole e il ruolo della farmacologia umana ed animale nella scelta di un farmaco antifungino Micologia Dermatol. 1990,4:247-256.
32. Heykants J, Van Peer A, Van de Velde V, et al. The clinical pharmacokinetics of itraconazole. an overview. Mycoses. 1989,32(suppl 1):67-87
33. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol. 1988;18:263-268.
34. Barone JA, Bierman RH, Colaizzi JL, et al. Food interactions and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother. 1993;37:778-784.
35. Piérard GE, Arrese JE, De Doncker P Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study J Am Acad Dermatol 1995;32:429-435.
36. Van Cutsem J. The in vitro evaluation of azoles. In: Iwata K, Van Den Bossche H, eds. In Vitro and In Vivo Evaluation of Antifungal Agents. Amsterdam, the Netherlands: Elsevier Science Publishers; 1986:51-64.
37. Greer DL. Clinical consequences of new pharmacological concepts in cutaneous fungal infections. J Eur Acad Dermatol Venereol. 1993;2:S26-S33
38. Willemsen M. Changing patterns in superficial infections, focus on onychomycosis J Eur Acad Dermatol Venereol. 1993;2:S6-S11.
39. Arrese JE, Piérard-Franchimont C, Greimers R. Piérard GE. Fungi in onychomycosis: a study by immunohistochemistry and dual flow cytometry. J Eur Acad Dermatol Venereol. 1995;4:123-130
40. Ramani R, Srinivas CR, Ramani A, Kumari TGR, Shivananda PG. Molds in onychomycosis Int J Dermatol. 1993,32 877-878
41. De Doncker P. Pharmacokinetics: basis for research in fungal nail disease. Med Monitor. 1994;1:6-7.
42. Matthieu L, De Doncker P, Cauwenbergh G et al Itraconazole penetrates the nail via the nail matrix and the nail bed: an investigation in onychomycosis. Clin Exp Dermatol. 1992;16:374-376
43. Haneke E Therapie der Nagelmykosen. Hautartz. 1993;44:335-346.
44. Degreef H. Onychomycosis. Br J Clin Pract. 1990;9(suppl 71):91-97.
45. Hay RJ, Clayton YM, Moore MK, Midgely G. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol. 1988;119:359-366.
46. Roseeuw D, de Doncker P New therapeutic concepts for the treatment of onychomycosis. J Eur Acad Dermatol Venereol. 1993;2(suppl 1):S34-S38.
47. Walsóe I, Stangerup M, Svejgaard E Itraconazole in onychomycosis: open and double-blind studies Acta Derm Venereol 1990;70:137-140.
48. Rongioletti F, Robert E, Tripodi S, Persi A. Treatment of onychomycosis with itraconazole. J Dermatol Treat 1992,2:145-146.
49. Willemsen M, De Doncker P, Willems J, et al. Post-treatment itraconazole levels in the nail. J Am Acad Dermatol. 1992;26.731-735.
50. Baran R, Dawber RPR. Physical signs. In: Baran R, Dawber R, eds. Diseases of the Nail and Their Management. 2nd ed. Boston, Mass: Blackwell Scientific Publications Inc; 1994:35-80.
51. Haneke E, Plinck JB, Delescluse J. Itraconazole in onychomycosis. Eur J Dermatol. In press.
52. Roseeuw D, De Doncker P New approaches to the treatment of onychomycosis. J Am Acad Dermatol. 1993 29.S45-S50.
53. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995:34, 138-143.
54. Hay RH. Clinical Expert Report on 200 mg Itraconazole Daily for 3 Months in the Treatment of Onychomycosis: International Registration File. Beerse, Belgium: Janssen Research Foundation: 1993.
55. Hay RH. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol. 1993;29:S50-S54
56. Gupta AK, Sauder DN, Shear NH Antifungal agents, II: an overview J Am Acad Dermatol. 1994,30 911-933.
57. Heremans A. Clinical Expert Report on Itraconazole for the Treatment of Onychomycosis With a Shortened Regimen of 200 mg bid 1 Week/Month for 2 or 3 Months: International Registration File. Beerse, Belgium: Janssen Research Foundation; 1995.
58. Woestenborghs R, Lorreyne W, Heykants J Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1987;413:332-337
59. De Doncker P. Pharmacokinetics: basis for research in fungal nail disease. Clin Couryer. 1994;12:6-7.
60. Dykes PJ, Thomas R, Finlay AY. Determination of terbinafine in nail samples during systemic treatment for onychomycoses Br J Dermatol. 1990;123:481-486.
61. Finlay AY, Lever LR, Thomas R, Dykes PJ Nail matrix kinetics of oral terbinafine in onychomysosts and normal nails. J Dermatol Treat 1990;1(suppl 2) 51-54.
62. Finlay AY Pharmacokinetics of terbinafine in the nail Br J Dermatol. 1992, 126(suppl 39):28-32
63. Jenssen JC Pharmacokinetics in humans. J Dermatol Treat 1990;1(suppl 2): 15-18
64. Lever LR, Dykes PJ, Thomas R, Finlay AY. How orally administered terbinafine reaches the stratum corneum. J Dermatol Treat. 1990;1(suppl 2):23-26.
65. Faerjemann J, Zehender H, Jones T, Maibach I. Terbinafine levels in serum, stratum corneum, demis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol Suppl (Stockh). 1990,71:322-326
66. Shuster S, Munro CS. Single-dose treatment of fungal nail disease. Lancet. 1992;339-1066.
67. André J. Itraconazole pulse therapy in onychomycosis: European experience. Clin Couryer. 1995:13:4-5
68. De Doncker P, Van Lint J, Dockx P, Roseeuw D. Pulse therapy with one-week itraconazole monthly for 3 or 4 months in the treatment of onychomycosis. Cutis. 1995,56:180-183.
69. Ginter G Intermittent therapy with itraconazole: a new approach to the treatment of onychomycosis In: Elweksi B, Scher B, Odom R, eds. Proceedings of the Second Annual International Summit on Cutaneous Antifungal Therapy; November 1994; Boston, Mass.